Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the last patient has completed the treatment phase in REVIVE-2, the second Phase
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of
Richard Morgan, Chairman of Motif Bio, commented: “I am delighted to welcome Craig to the Board of Motif Bio. We have seen great progress in the development of iclaprim, our
Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, have announced today positive topline results from REVIVE-1, a global Phase 3 clinical trial of its
Northland Capital partners view on Motif Bio Plc LON:MTFB: In line with our expectations, Motif Bio announced that the last patient has finished treatment in its first pivotal Phase 3
Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), a late clinical stage antibiotic development company, has announced that the treatment phase has finished for the last patient in REVIVE-1, the first of two
Commenting on this milestone, Graham Lumsden, CEO of Motif Bio LON:MTFB, said: “Thanks to the patients and investigators who participated in REVIVE-1, we remain on track to be able to
Northland Capital Partners’ Vadim Alexandre discusses ImmuPharma PLC in this exclusive interview with DirectorsTalk
Zeus Capital’s Dr Gary Waanders discusses Motif Bio PLC in this exclusive interview with DirectorsTalk
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
